BridgeBio Pharma BBIO Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's other non-current assets?
- BridgeBio Pharma (BBIO) reported other non-current assets of $18.62M in Q1 2026.
- How has BridgeBio Pharma's other non-current assets changed year-over-year?
- BridgeBio Pharma's other non-current assets increased by 12.1% year-over-year, from $16.61M to $18.62M.
- What is the long-term trend for BridgeBio Pharma's other non-current assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.
- What does other non-current assets mean?
- A collection of miscellaneous long-term assets that do not fall into specific reporting categories.
- How do you interpret other non-current assets?
- An increase may indicate new long-term investments or deposits, while a decrease suggests the realization or impairment of these assets.
- How does other non-current assets compare across companies?
- Peers typically maintain low levels of other non-current assets; significant spikes often warrant investigation into non-core investments.